The United Kingdom and the United States have agreed to a major commercial pact that will keep zero import taxes on UK medicine exports going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise expenditure on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital exports will remain at nothing for a duration of three years.
This agreement comes after previous threats to significantly raise import taxes on branded drug products, with increases mentioned as high as 100%.
"This agreement with the United Kingdom strengthens the international landscape for innovative medicines and brings much-needed equity to transatlantic medicine commerce," a statement noted.
Economic Impact
Pharmaceuticals are one of the UK's most significant export categories to the US, which is easily the biggest destination for leading British pharmaceutical firms.
Statistics indicate that in the year to the end of the third quarter, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This figure made up a significant portion of British export trade in that period.
"This agreement protects work, increases investment and paves the way for the UK to become a international leader for medical research," a government official commented.
Key UK Commitments
The deal includes several notable commitments from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to raise total health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, repayments exceeded twenty percent.
Industry Background
This agreement takes place against a long-running dispute between the sector and the ministers over medicine costs and NHS adoption.
These tensions were heightened by assertions that US patients were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
